Isn't that what Detroit is doing with all those cars they can't sell?
I'm just asking . . .
But I guess those "comprehensive plans that we believe will strengthen Lipitor's marketposition," from the first quarter really didn't work out . . .
And the fantastic FIVE NEW INDICATIONS . . . no one cared about them.
At least not prescribing docs.
But there is more.
Since Pfizer's drugs lose patents faster than a seven year old loses her teeth, Pfizer has invented a new measurement:
"Pharmaceutical adjusted revenues, which excludes the revenues of major products which have lost exclusivity in the U.S. since the beginning of 2006."
Pfizer hopes by using this measurement, and comparing this number from year to year, they'll show investors how well they do on products that don't lose their patents.
But only a drug company in mortal fear of future patent losses would introduce such a measurement.
And, just to be on the safe side, Pfizer Inc adds:
"This additional revenue measure is not, and should not be viewed as, a substitute for the U.S. GAAP comparison of Pharmaceutical revenue."
If you're a Pfizer investor, this ain't really funny. But if you aren't, this is the greatest smoke and mirror show in town.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).
